2022
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade
Gomez-Roca C, Cassier P, Zamarin D, Machiels JP, Gracia J, Hodi F, Taus A, Garcia M, Boni V, Eder JP, Hafez N, Sullivan R, Mcdermott D, Champiat S, Aspeslagh S, Terret C, Jegg AM, Jacob W, Cannarile MA, Ries C, Korski K, Michielin F, Christen R, Babitzki G, Watson C, Meneses-Lorente G, Weisser M, Rüttinger D, Delord JP, Marabelle A. Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade. Journal For ImmunoTherapy Of Cancer 2022, 10: e004076. PMID: 35577503, PMCID: PMC9114963, DOI: 10.1136/jitc-2021-004076.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerUrothelial bladder cancerObjective response rateOptimal biological doseImmune checkpoint blockersUBC patientsConfirmed objective response rateTreatment-related adverse eventsCell death 1 ligandPhase 1b studyManageable safety profileImmune checkpoint blockadeCell lung cancerDeath 1 ligandAtezolizumab monotherapyPatients naïveAdverse eventsCheckpoint blockadeCheckpoint blockersNSCLC patientsSkin rashDose escalationClinical benefitSafety profileLung cancer
2021
Clinical Efficacy of Olaparib in IDH1/IDH2-Mutant Mesenchymal Sarcomas
Eder JP, Doroshow DB, T. K, Keedy VL, Sklar JS, Glazer P, Bindra R, Shapiro GI. Clinical Efficacy of Olaparib in IDH1/IDH2-Mutant Mesenchymal Sarcomas. JCO Precision Oncology 2021, 5: 466-472. PMID: 34994649, PMCID: PMC9848565, DOI: 10.1200/po.20.00247.Peer-Reviewed Original ResearchConceptsPulmonary epithelioid hemangioendotheliomaStable diseaseEpithelioid hemangioendotheliomaClinical benefitClinical benefit rateOpen-label studyPrimary end pointPoly (ADP-ribose) polymerase inhibitionDefective homologous recombination (HR) repairMesenchymal sarcomaObjective responsePartial responseClinical efficacyPatient populationBenefit rateCombination trialsPatientsSolid tumorsIDH1/2-mutant tumorsIDH1/2 mutationsPARP inhibitorsEnd pointPARP inhibitionTumorsOlaparib